In September, U.S. pharmaceutical company, Gilead Sciences Inc. entered into a licence agreement with seven Indian pharmaceutical companies (the licensees), allowing them to manufacture their own, lower cost, generic versions of Sovaldi, the Hepatitis C (HCV) drug patented by Gilead. The Indian companies on this unique initiative are CIPLA, Ranbaxy, Cadila Healthcare, Hetero Labs, Mylan Laboratories, Sequent Scientific and Stride Arcolab.
Examining the Gilead deal
Kunal Nathwani, Research Intern, Gateway House, has written an article analyzing the Gilead Licensing Agreement with seven Indian Pharmaceutical Companies. This article has been republished by The Political Indian